Cancer recurrence or aggravation following COVID-19 vaccination

Q3 Medicine Journal of Nephropharmacology Pub Date : 2023-04-15 DOI:10.34172/npj.2023.10593

Parisa Soleimani, Sepideh Yadollahifarsani, M. Motieian, Mahshid Sadat Chenarani Moghadam, S. Alimohammadi, Azadeh Khayyat, Mohammad Ali Esmaeil pour, Sina Neshat, Narges Alsadat Marashi, Leila Mahmoodnia, Rohollah Masomi

{"title":"Cancer recurrence or aggravation following COVID-19 vaccination","authors":"Parisa Soleimani, Sepideh Yadollahifarsani, M. Motieian, Mahshid Sadat Chenarani Moghadam, S. Alimohammadi, Azadeh Khayyat, Mohammad Ali Esmaeil pour, Sina Neshat, Narges Alsadat Marashi, Leila Mahmoodnia, Rohollah Masomi","doi":"10.34172/npj.2023.10593","DOIUrl":null,"url":null,"abstract":"COVID-19 infection has been a global health issue in the past recent years and numerous topics are studied in order to discover its pathophysiology and potential side effects. The potential for disease recurrence following the administration of the COVID-19 vaccine is one of the issues that has recently attracted attention. Several studies have revealed that the COVID-19 vaccines, like other vaccines, may have side effects and, in some cases, they may even deteriorate the underlying illnesses, such as rheumatic diseases, autoimmune diseases, and cancers. The effectiveness and safety of the COVID-19 vaccine for patients with malignancies are one of the factors that are considered regarding this vaccine. Lymph node involvement, disease recurrence, and potential paraclinical changes after receiving the COVID-19 vaccine are some of the concerns of patients with malignancy. In this mini-review, we attempted to investigate cases of cancer recurrence or recovery as well as lymphadenopathy following vaccination.","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nephropharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/npj.2023.10593","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

COVID-19 infection has been a global health issue in the past recent years and numerous topics are studied in order to discover its pathophysiology and potential side effects. The potential for disease recurrence following the administration of the COVID-19 vaccine is one of the issues that has recently attracted attention. Several studies have revealed that the COVID-19 vaccines, like other vaccines, may have side effects and, in some cases, they may even deteriorate the underlying illnesses, such as rheumatic diseases, autoimmune diseases, and cancers. The effectiveness and safety of the COVID-19 vaccine for patients with malignancies are one of the factors that are considered regarding this vaccine. Lymph node involvement, disease recurrence, and potential paraclinical changes after receiving the COVID-19 vaccine are some of the concerns of patients with malignancy. In this mini-review, we attempted to investigate cases of cancer recurrence or recovery as well as lymphadenopathy following vaccination.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

COVID-19疫苗接种后癌症复发或加重

近年来，新冠肺炎感染一直是一个全球性的健康问题，为了发现其病理生理学和潜在的副作用，对许多主题进行了研究。新冠肺炎疫苗接种后疾病复发的可能性是最近引起关注的问题之一。几项研究表明，新冠肺炎疫苗与其他疫苗一样，可能会产生副作用，在某些情况下，甚至可能恶化潜在疾病，如风湿性疾病、自身免疫性疾病和癌症。新冠肺炎疫苗对恶性肿瘤患者的有效性和安全性是该疫苗考虑的因素之一。接受新冠肺炎疫苗后，淋巴结受累、疾病复发和潜在的临床旁变化是恶性肿瘤患者的一些担忧。在这篇小型综述中，我们试图调查癌症复发或恢复的病例，以及接种疫苗后的淋巴结病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊